Quantcast
Last updated on April 20, 2014 at 17:20 EDT

Boehringer Ingelheim Selects ChemAxon to Power Next-Generation Global Cheminformatics Platform

February 14, 2013

BUDAPEST, Hungary & BOSTON, February 14, 2013 /PRNewswire/ –

Leading pharmaceutical company continues the trend of building future cheminformatics
platforms on ChemAxon technology

ChemAxon [http://www.chemaxon.com ], a leader in providing chemistry software
solutions and consulting services for life science research, announces that Boehringer
Ingelheim has chosen its chemistry software platform for multiple applications across
research and development, supporting in-house activities and work with external
collaboration partners. ChemAxon technology will be used to store, search, calculate, and
visualize chemical entities, properties and reactions, helping to streamline the
progression from drug discovery to clinical candidate. ChemAxon was chosen after an
extensive evaluation process that built on dimensions such as ROI, performance,
robustness, scalability and future development roadmap.

ChemAxon sets the standard in chemically-intelligent software for pharmaceutical R&D.
With a client list that includes all of the top 15 global pharma companies, the company
continues to experience significant growth year on year.

Commenting on the agreement, Alex Drijver, CEO of ChemAxon said, “The adoption of
ChemAxon technology by Boehringer Ingelheim further underlines our position as the
platform of choice for R&D organizations planning their next-generation systems.”

To discover more about how ChemAxon’s leading edge cross-platform solutions power
modern cheminformatics and chemical communication, please visit

http://www.chemaxon.com

About ChemAxon
ChemAxon [http://www.chemaxon.com ] is a leader in providing cheminformatics software
platforms and desktop applications for the biotechnology, pharmaceutical and agrochemical
industries. With core capabilities for structure visualization, search and management,
property prediction, virtual synthesis, screening and drug design, ChemAxon focuses upon
active interaction with users and software portability to create powerful, cost effective
cross platform solutions that power modern cheminformatics and chemical communication. The
company is privately owned with European headquarters in Budapest, US East Coast
headquarters in Cambridge, MA, and sales and support offices in Europe, Japan and across
North America.

SOURCE ChemAxon Ltd.


Source: PR Newswire